The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Recurrent Clostridioides difficile Colitis

Repeat episodes of C. difficile infection within 8 weeks of completed therapy, managed with fidaxomicin, bezlotoxumab, fecal microbiota transplantation, and antibiotic stewardship.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dahiliye (İç Hastalıkları) department. Book Appointment →

What is Recurrent Clostridioides difficile Colitis?

Recurrent Clostridioides difficile infection (rCDI) is a return of diarrhea and a positive C. difficile test within 8 weeks of completing therapy. Distinguishing relapse (same strain) from reinfection (different strain) typically requires molecular typing and is largely academic since clinical management is similar; the underlying issue is persistent dysbiosis, residual spores, and inadequate adaptive immunity to toxins A and B.

Risk factors include advanced age, antibiotic exposure during or after CDI treatment, proton pump inhibitor use, immunosuppression, multiple comorbidities, prior recurrence, healthcare exposure, and presence of hypervirulent strains (NAP1/BI/027). Recurrence rates rise from approximately 20-30% after a first episode to over 60% after multiple episodes due to compounding microbiome injury.

Diagnosis requires unformed stool plus a positive test (NAAT plus toxin EIA two-step algorithm preferred). Severity is graded using leukocyte count, creatinine, albumin, and clinical signs of fulminant colitis (ileus, megacolon, shock). Management combines targeted antibiotics, microbiome restoration, monoclonal antibody (bezlotoxumab), supportive care, and prevention; surgical evaluation is needed for fulminant or perforated disease.

Symptoms

Recurrence of watery diarrhea three or more times daily
Crampy lower abdominal pain and tenesmus
Low-grade fever, chills, fatigue
Dehydration, hypotension, electrolyte disturbance
Leukocytosis, hypoalbuminemia, rising creatinine
Severe disease: bloody stools, ileus, toxic megacolon
Symptom onset within 8 weeks of completing CDI therapy

Risk Factors

Age over 65 and frailty
Antibiotic use during or after the index CDI episode
Proton pump inhibitor and H2 blocker use
Immunosuppression, chemotherapy, IBD, transplant, end-stage renal disease
Prior CDI episode and hospitalization or long-term care residence
Hypervirulent strains (NAP1/BI/027)
Inadequate humoral immune response to toxin B

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Recurrent diarrhea after recent CDI therapy
  • Severe abdominal pain, fever, or bloody stools
  • Signs of dehydration, hypotension, or worsening renal function
  • Suspicion of toxic megacolon or fulminant colitis
  • After two or more recurrences for consideration of fecal microbiota transplantation
  • When immunosuppressed or after transplant for individualized therapy
  • Persistent symptoms despite ongoing therapy

Treatment Methods

01
First recurrence: fidaxomicin 200 mg twice daily for 10 days (preferred) or vancomycin tapered/pulsed regimen if fidaxomicin unavailable
02
Second or subsequent recurrence: vancomycin tapered/pulsed (e.g., 125 mg QID 10-14 d, then BID, daily, every 2-3 days for total 4-6 weeks) or fidaxomicin extended pulse regimen
03
Adjunctive bezlotoxumab single IV infusion (10 mg/kg) to neutralize toxin B and reduce recurrence risk in high-risk patients
04
Fecal microbiota transplantation (FMT) for multiply recurrent disease (≥2 recurrences) with sustained cure rates above 80%
05
FDA-approved live biotherapeutic products such as fecal microbiota live-jslm (RBX2660) or SER-109 to prevent recurrence after standard antibiotics
06
Antibiotic stewardship: minimize unnecessary antibiotics, narrow spectrum, shorten duration; review proton pump inhibitor indications
07
Infection prevention: hand hygiene with soap and water, contact isolation, sporicidal cleaning; nutritional support, hydration, and avoidance of antimotility agents in moderate-severe disease

Which Department to Visit?

You can visit our Dahiliye (İç Hastalıkları) department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dahiliye (İç Hastalıkları) Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.